| Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow Y Shiozawa, EA Pedersen, AM Havens, Y Jung, A Mishra, J Joseph, ... The Journal of clinical investigation 121 (4), 1298-1312, 2011 | 825 | 2011 |
| The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer J Wang, Y Shiozawa, J Wang, Y Wang, Y Jung, KJ Pienta, R Mehra, ... Journal of Biological Chemistry 283 (7), 4283-4294, 2008 | 653 | 2008 |
| Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo RD Loberg, C Ying, M Craig, LL Day, E Sargent, C Neeley, K Wojno, ... Cancer research 67 (19), 9417-9424, 2007 | 406 | 2007 |
| GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche Y Shiozawa, EA Pedersen, LR Patel, AM Ziegler, AM Havens, Y Jung, ... Neoplasia 12 (2), 116-IN4, 2010 | 373 | 2010 |
| The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis J Wang, R Loberg, RS Taichman Cancer and Metastasis Reviews 25, 573-587, 2006 | 327 | 2006 |
| CCL2 is a potent regulator of prostate cancer cell migration and proliferation RD Loberg, LSL Day, J Harwood, C Ying, LNS John, R Giles, CK Neeley, ... Neoplasia 8 (7), 578-586, 2006 | 311 | 2006 |
| A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression CL Buller, RD Loberg, MH Fan, Q Zhu, JL Park, E Vesely, K Inoki, ... American Journal of Physiology-Cell Physiology 295 (3), C836-C843, 2008 | 291 | 2008 |
| CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration RD Loberg, C Ying, M Craig, LI Yan, LA Snyder, KJ Pienta Neoplasia 9 (7), 556-562, 2007 | 278 | 2007 |
| Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer Y Shiozawa, AM Havens, Y Jung, AM Ziegler, EA Pedersen, J Wang, ... Journal of cellular biochemistry 105 (2), 370-380, 2008 | 277 | 2008 |
| CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases MJ Craig, RD Loberg Cancer and Metastasis Reviews 25, 611-619, 2006 | 220 | 2006 |
| The lethal phenotype of cancer: the molecular basis of death due to malignancy RD Loberg, DA Bradley, SA Tomlins, AM Chinnaiyan, KJ Pienta CA: a cancer journal for clinicians 57 (4), 225-241, 2007 | 203 | 2007 |
| A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone X Li, R Loberg, J Liao, C Ying, LA Snyder, KJ Pienta, LK McCauley Cancer research 69 (4), 1685-1692, 2009 | 199 | 2009 |
| Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism RD Loberg, E Vesely, FC Brosius Journal of Biological Chemistry 277 (44), 41667-41673, 2002 | 196 | 2002 |
| The evolving biology and treatment of prostate cancer RS Taichman, RD Loberg, R Mehra, KJ Pienta The Journal of clinical investigation 117 (9), 2351-2361, 2007 | 191 | 2007 |
| A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the … CS Fuchs, S Azevedo, T Okusaka, JL Van Laethem, LR Lipton, H Riess, ... Annals of Oncology 26 (5), 921-927, 2015 | 186 | 2015 |
| Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype RD Loberg, CJ Logothetis, ET Keller, KJ Pienta Journal of clinical oncology 23 (32), 8232-8241, 2005 | 165 | 2005 |
| A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer AL Cohn, J Tabernero, J Maurel, E Nowara, J Sastre, BYS Chuah, ... Annals of oncology 24 (7), 1777-1785, 2013 | 113 | 2013 |
| Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin … WWJ de Leng, CG Gadellaa-van Hooijdonk, FAS Barendregt-Smouter, ... PloS one 11 (2), e0149405, 2016 | 110 | 2016 |
| The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications KC Anderson, D Auclair, GJ Kelloff, CC Sigman, H Avet-Loiseau, ... Clinical Cancer Research 23 (15), 3980-3993, 2017 | 103 | 2017 |
| PAR1‐mediated NFκB activation promotes survival of prostate cancer cells through a Bcl‐xL‐dependent mechanism K Tantivejkul, RD Loberg, SC Mawocha, LL Day, LS John, BA Pienta, ... Journal of cellular biochemistry 96 (3), 641-652, 2005 | 100 | 2005 |
